7
Clinical Trials associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)A Study of BCMA CAR-T for Dynamic High-risk Patients With Multiple Myeloma
This is a single-arm, open-label study to evaluate the efficacy and safety of BCMA CAR-T in dynamic high-risk patients with multiple myeloma
A Prospective, Non-inferiority Study Comparing VRD±D Followed by BCMA CAR-T Cell Therapy Versus VRD±D Followed by Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Patients With Newly-diagnosed Multiple Myeloma
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.
Safety and Efficiency of VRd Combining BCMA CAR-T Regimen for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia
Start Date01 Jul 2023 |
Sponsor / Collaborator- |
100 Clinical Results associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)
100 Translational Medicine associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)
100 Patents (Medical) associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)
100 Deals associated with Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital)